FDA warned VitaCig that its flavored inhalers and capsules are unapproved new drugs sold with disease-treatment claims on its website.
What happened
FDA reviewed the company's website at vitaciggroup.com in September 2021 and found it takes orders there for VitaCig inhalers and capsules. The site's claims, such as easing anxiety, aiding weight loss and improving memory or focus, show the products are intended to treat disease or affect body function, so FDA treats them as new drugs with no approved application. FDA also said inhaling these ingredients and impurities could trigger airway spasms, harm airway tissue, or cause toxic effects elsewhere in the body.
What FDA found
The products are new drugs sold without the FDA approval the law requires.
FD&C Act sections 505(a) and 301(d), 21 U.S.C. 355(a) and 331(d)Website claims that the products treat conditions or change how the body works make them drugs under the law.
FD&C Act section 201(g)(1), 21 U.S.C. 321(g)(1)The products are not generally recognized as safe and effective for the uses claimed on the website.
FD&C Act section 201(p), 21 U.S.C. 321(p)Shipping these unapproved products across state lines is a prohibited act.
FD&C Act section 301(d), 21 U.S.C. 331(d)
What FDA wants
FDA tells the company to write back within fifteen working days describing the specific steps taken to fix the violations, how it will prevent them from recurring, and to include supporting documents. If the company believes its products are legal, it must explain why with supporting information; if it needs more time, it must say why and give a date.
Who should pay attention
- online sellers and marketplaces listing inhaler or aromatherapy devices
- companies making inhaled or essential-oil products with health claims
- firms whose websites describe symptom relief or health benefits
This is a summary. Read the original letter on fda.gov.